ERBB2 and triple-negative breast carcinoma: Given that the association between treatment response and prognosis differs across molecular subtypes, future work should consider stratified models tailored to individual subtypes such as Luminal A, Luminal B, HER2-enriched, and triple-negative breast cancers.